Latest & greatest articles for hydrochlorothiazide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydrochlorothiazide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydrochlorothiazide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydrochlorothiazide

21. Amturnide (amlodipine/aliskiren/hydrochlorothiazide)

Amturnide (amlodipine/aliskiren/hydrochlorothiazide) Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Amturnide (amlodipine/aliskiren/hydrochlorothiazide) 150/5/12.5 mg, 300/5/12.5 mg, 300/5/25 mg, 300/10/12.5 mg and 300/10/25 mg Tablets Company: Novartis Pharmaceuticals Application No.: 200045 Approval Date: 12/21/2010 Persons with disabilities having problems

2010 FDA - Drug Approval Package

22. Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide)

Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide) Drug Approval Package: TRIBENZOR (olmesartan medoxomil and amlodipine) NDA #200175 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - TRIBENZOR (olmesartan medoxomil / amlodipine / hydrochlorothiazide) Tablets Company: Daiichi Sankyo, Inc. Application No.: 200175 Approval Date: 07/23/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2010 FDA - Drug Approval Package

23. Olmesartan medoxomil + hydrochlorothiazide - Hypertension

Olmesartan medoxomil + hydrochlorothiazide - Hypertension Common Drug Review CEDAC Meeting – April 15, 2009 Page 1 of 2 Notice of CEDAC Final Recommendation – May 27, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION OLMESARTAN MEDOXOMIL /HYDROCHLOROTHIAZIDE (Olmetec Plus ® – Schering-Plough Canada Inc.) Indication: Mild to Moderate Essential Hypertension Description: Olmetec Plus is a combination product containing an angiotensin II receptor blocker (ARB), olmesartan (...) , and a thiazide diuretic, hydrochlorothiazide. Olmetec Plus is indicated for the treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. It is not indicated for the initial treatment of hypertension and patients should be titrated to a stable dose of the individual components prior to initiation of therapy with Olmetec Plus. Dosage Forms: Suppled as tablets containing olmesartan medoxomil/hydrochlorothiazide in the following ratio: 20 mg/12.5 mg, 40 mg

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

24. Copalia HCT - amlodipine / valsartan / hydrochlorothiazide

Copalia HCT - amlodipine / valsartan / hydrochlorothiazide European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: mail@emea.europa.eu http://www.emea.europa.eu Doc.Ref: EMEA/CHMP/471143/2009 ASSESSMENT REPORT FOR Copalia HCT International Nonproprietary Name: amlodipine besylate / valsartan / hydrochlorothiazide Procedure No. EMEA/H/C/001159 Assessment Report as adopted (...) new fixed combination products. The applicant applied for the following indication: “Treatment of essential hypertension. Copalia HCT is indicated as replacement therapy in patients whose blood pressure is adequately controlled on amlodipine, valsartan and hydrochlorothiazide (HCT) used as individual or combination therapies”. Information on Paediatric requirements Pursuant to Article 7, the application included an EMEA Decision P/14/2009 for the following condition: • Essential hypertension

2009 European Medicines Agency - EPARs

25. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan (PubMed)

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan There is large interindividual variability in the antiproteinuric response to blockade of the renin-angiotensin-aldosterone system (RAAS). A low-sodium diet or addition of diuretics enhances the effects of RAAS blockade on proteinuria and BP, but the efficacy of the combination of these interventions is unknown. Therefore, this randomized, double-blind, placebo-controlled trial to determine (...) the separate and combined effects of a low-sodium diet and hydrochlorothiazide (HCT) on proteinuria and BP was performed. In 34 proteinuric patients without diabetes, mean baseline proteinuria was 3.8 g/d, and this was reduced by 22% by a low-sodium diet alone. Losartan monotherapy reduced proteinuria by 30%, and the addition of a low-sodium diet led to a total reduction by 55% and the addition of HCT to 56%. The combined addition of HCT and a low-sodium diet reduced proteinuria by 70% from baseline (all P

Full Text available with Trip Pro

2008 EvidenceUpdates

26. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. (PubMed)

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting-enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus (...) a thiazide diuretic.In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.The baseline characteristics

2008 NEJM

27. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden

Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden Ekman M, Bienfait-Beuzon C, Jackson J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of irbesartan in combination with hydrochlorothiazide in comparison with other selective angiotensin-II-receptor blockers. The authors concluded that irbesartan combined with hydrochlorothiazide was a cost-effective alternative to valsartan and losartan

Full Text available with Trip Pro

2008 NHS Economic Evaluation Database.

28. Ramipril/hydrochlorothiazide - Hypertension

Ramipril/hydrochlorothiazide - Hypertension Common Drug Review CEDAC Meeting – May 16, 2007 Page 1 of 2 Notice of Final CEDAC Recommendation – June 14, 2007 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION RAMIPRIL/HYDROCHLOROTHIAZIDE (Altace ® HCT Resubmission – Sanofi-Aventis Canada Inc.) Description: Altace ® HCT is a fixed dose combination of ramipril and hydrochlorothiazide. It is approved for the treatment of essential hypertension in patients for whom this combination therapy (...) is appropriate. Altace ® HCT is not indicated for initial therapy and patients should be titrated to a stable dose of the individual components prior to initiation of therapy with Altace ® HCT. Dosage Forms: Tablets containing ramipril/hydrochlorothiazide in the following ratio: 2.5 mg/12.5 mg, 5 mg/12.5 mg, 5 mg/25 mg, 10 mg/12.5 mg, 10 mg/25 mg. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that Altace ® HCT be listed. Reasons for the Recommendation: 1. Altace ® HCT costs

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

29. CoAprovel - irbesartan / hydrochlorothiazide

CoAprovel - irbesartan / hydrochlorothiazide 1 ?EMEA 2004 SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures which have been finalised before 1 November 2004. For scientific information on procedures after this date please refer to module 8B. 1. Introduction The application is a new combination of two previously known active substances in the combinations 150 mg/12.5 mg and 300 mg/12.5 mg of irbesartan and hydrochlorothiazide (...) as an alternative to the titration to 300 mg of irbesartan in subjects not adequately controlled by 150 mg irbesartan or hydrochlorothiazide alone. Similarly, the dose of 300 mg/12.5 mg is proposed as an additional useful step for the subjects not adequately controlled by the combination 150 mg/12.5 mg or by 300 mg monotherapy. 2. Part II: Chemical, pharmaceutical and biological aspects Uncoated tablets Composition The medicinal product is available in the form of tablets with doses of 150 mg/12.5 mg and 300 mg

2006 European Medicines Agency - EPARs

30. eprosartan mesylate/ hydrochlorothiazide

eprosartan mesylate/ hydrochlorothiazide CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION EPROSARTAN MESYLATE/HYDROCHLOROTHIAZIDE (Teveten® Plus – Solvay Pharma Inc.) Description: Teveten® Plus is a combination product containing an angiotensin II receptor blocker (ARB), eprosartan mesylate 600 mg, and a thiazide diuretic, hydrochlorothiazide (HCTZ) 12.5mg. This combination is indicated for the treatment of mild to moderate essential hypertension in patients for whom combination (...) therapy is appropriate. It is not indicated for initial therapy. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that this eprosartan/ hydrochlorothiazide combination be listed in a similar manner as drug plans list other ARB/HCTZ combination products. Reasons for the recommendation: 1. Two randomized trials found that the combination of eprosartan and HCTZ provided greater blood pressure lowering than monotherapy using either agent. 2. The combination product

2004 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

31. Micardis HCT (telmisartan/hydrochlorothiazide)

Micardis HCT (telmisartan/hydrochlorothiazide) Drug Approval Package: Micardis HCT (telmisartan/hydrochlorothiazide) NDA #021162 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Micardis HCT (telmisartan/hydrochlorothiazide) Tablets Company: Boehringer Ingelheim Application No.: 021162 Approval Date: 11/17/2000 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: March 112004

2000 FDA - Drug Approval Package

32. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. (PubMed)

Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. To compare the effectiveness and tolerability of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in patients with mild to moderate hypertension.Randomised multicentre trial over 48 weeks with double blind comparison of treatments.48 centres in four countries.868 patients with essential (...) hypertension (diastolic blood pressure 95-120 mm Hg)Initial treatment (step 1) consisted of 12.5 mg hydrochlorothiazide (n = 215), 25 mg atenolol (n = 215), 10 mg nitrendipine (n = 218), or 5 mg enalapril (n = 220) once daily. If diastolic blood pressure was not reduced to < 90 mm Hg within four weeks, doses were increased to 25 mg, 50 mg, 20 mg, 10 mg, respectively, once daily (step 2) and after two more weeks to twice daily (step 3). The eight week titration phase was followed by an additional 40 weeks

Full Text available with Trip Pro

1997 BMJ

33. METHYLDOPA AND HYDROCHLOROTHIAZIDE IN PRIMARY HYPERTENSION: CONTROLLED CLINICAL TRIAL OF DRUGS SINGLY AND IN COMBINATION. (PubMed)

METHYLDOPA AND HYDROCHLOROTHIAZIDE IN PRIMARY HYPERTENSION: CONTROLLED CLINICAL TRIAL OF DRUGS SINGLY AND IN COMBINATION. 14043085 1996 12 01 2019 02 21 0098-7484 185 1963 Sep 14 JAMA JAMA METHYLDOPA AND HYDROCHLOROTHIAZIDE IN PRIMARY HYPERTENSION: CONTROLLED CLINICAL TRIAL OF DRUGS SINGLY AND IN COMBINATION. 819-25 WILSON W R WR OKUN R R TETREAULT L L eng Journal Article United States JAMA 7501160 0098-7484 0 Antihypertensive Agents 0J48LPH2TH Hydrochlorothiazide 56LH93261Y Methyldopa OM (...) Antihypertensive Agents Essential Hypertension Humans Hydrochlorothiazide Hypertension Methyldopa ANTIHYPERTENSIVE AGENTS HYDROCHLOROTHIAZIDE METHYLDOPA 1963 9 14 1963 9 14 0 1 1963 9 14 0 0 ppublish 14043085

1996 JAMA

34. Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. (PubMed)

Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. To compare the effects of sodium depletion and of angiotensin I converting enzyme inhibition on microalbuminuria in insulin dependent diabetes.Randomised, double blind, double dummy parallel study of normotensive diabetic patients with persistent microalbuminuria (30-300 mg/24 h) treated with enalapril or hydrochlorothiazide for one year after a three month (...) , single blind placebo period.Diabetic clinic in a tertiary referral centre.10 diabetic patients with low microalbuminuria (30-99 mg/24 h) and 11 with high microalbuminuria (100-300 mg/24 h).11 subjects (six with low microalbuminuria, five with high microalbuminuria) were given enalapril 20 mg plus placebo hydrochlorothiazide once daily and 10 (four with low microalbuminuria, six with high microalbuminuria) hydrochlorothiazide 25 mg plus placebo enalapril once daily.Monthly assessment of urinary

Full Text available with Trip Pro

1993 BMJ

35. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. (PubMed)

An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. This multicenter, factorial-design trial assessed the safety and additive antihypertensive efficacy of a slow-release (SR) formulation of diltiazem hydrochloride given alone or in combination with hydrochlorothiazide for treatment of mild to moderate hypertension. After a 4- to 6-week placebo run-in period, 297 qualifying patients were (...) randomized to receive placebo, 1 of 4 doses of diltiazem SR monotherapy, 1 of 3 doses of hydrochlorothiazide monotherapy, or 1 of 12 possible combinations of diltiazem SR and hydrochlorothiazide for 6 weeks. A dose-related reduction in blood pressure was demonstrated for each drug as monotherapy and for the two drugs in combination. Absolute blood pressures of patients who received combination therapy were lower by an overall mean of 3.0 mm Hg diastolic and 8.0 mm Hg systolic vs diltiazem SR used alone

1990 JAMA

36. Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group. (PubMed)

Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group. To compare the efficacy and tolerability of hydrochlorothiazide, sustained release verapamil, and their combination in patients with mild to moderate hypertension.Randomised multicentre trial of 48 weeks' duration with a double blind comparison of hydrochlorothiazide and verapamil followed by an open trial of combined (...) treatment for patients not achieving the target diastolic blood pressure (less than 90 mm Hg) during treatment with a single drug.Outpatient departments in 10 clinics and 10 private practices of general practitioners or internists.369 Hypertensive patients with a diastolic blood pressure of 95-120 mm Hg during a placebo run in period of two weeks.Initial treatment consisted of 12.5 mg hydrochlorothiazide (n = 187) or 120 mg sustained release verapamil (n = 182) once daily (regimen I). If the target

Full Text available with Trip Pro

1989 BMJ

37. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. (PubMed)

A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. It has been suggested that the metabolic side effects of antihypertensive drugs are responsible for their failure to reduce cardiovascular morbidity in patients with hypertension. Therefore, in 50 patients with essential hypertension, we performed a randomized, double-blind, crossover study comparing the effects of carbohydrate and lipid metabolism of captopril (mean (...) [+/- SD] dose, 81 +/- 24 mg per day) and hydrochlorothiazide (40 +/- 12 mg per day) over two four-month treatment periods. Captopril increased the insulin-mediated disposal of glucose, as compared with placebo, from 5.7 +/- 2.4 to 6.3 +/- 2.5 mg per kilogram of body weight per minute (P less than 0.05), whereas hydrochlorothiazide caused a decrease from 6.4 +/- 2.0 to 5.7 +/- 1.9 (P less than 0.01). Captopril had no effect on the basal insulin concentration, but it decreased the late (30- to 90-minute

1989 NEJM

38. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. (PubMed)

Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. Enalapril, atenolol, and hydrochlorothiazide were compared in a double-blind randomised parallel study in general practice. 436 patients with mild to moderate hypertension were included at 76 centres. A two-week placebo run-in period was followed by 16 weeks of monotherapy. The initial doses were: enalapril 20 mg; atenolol 50 mg; and hydrochlorothiazide (...) 25 mg. These were doubled if treatment was not effective after 4 weeks. Adverse reactions were the main reason for withdrawal from the study (9 on enalapril, 19 on atenolol, and 8 on hydrochlorothiazide). Systolic and diastolic blood pressures were significantly reduced in all three groups. The reduction in systolic blood pressure was greater on enalapril than on atenolol. Serum potassium was reduced and uric acid increased on hydrochlorothiazide. Fasting blood sugar rose on atenolol but fell

1986 Lancet

39. Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study. (PubMed)

Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study. In a randomized double-blind study (N = 562), a traditional treatment schedule, starting antihypertensive treatment in elderly hypertensive patients (60 to 75 years old) with 25 mg of hydrochlorothiazide once daily and doubling the dose if a satisfactory response was not achieved, was compared with antihypertensive treatment of 100 mg (...) of metoprolol once daily, adding 12.5 mg of hydrochlorothiazide for patients whose response was not satisfactorialy achieved with metoprolol alone. Systolic and diastolic blood pressure was significantly reduced with both regimens. The frequency rates of responders (diastolic blood pressure, less than or equal to 95 mm Hg) in the metoprolol group and the hydrochlorothiazide group were 50% and 47% after four weeks and 65% and 61% after eight weeks, respectively. There were no significant differences in total

1986 JAMA

40. Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide. (PubMed)

Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide. In a crossover study of 26 hypertensive patients, the effects of triamterene (50 mg/day) and amiloride (5 mg/day) on urinary sediment were compared. Each drug was given for one month and all patients also received hydrochlorothiazide (50 mg/day). An abnormal urinary sediment--evident grossly as a reddish-brown precipitate after routine staining procedures and microscopically

1985 Lancet